Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.60
- Piotroski Score 6.00
- Grade In-Line
- Symbol (CRL)
- Company Charles River Laboratories International, Inc.
- Price $194.16
- Changes Percentage (3.33%)
- Change $6.26
- Day Low $186.74
- Day High $194.88
- Year High $275.00
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/12/2025
- Fiscal Year End N/A
- Average Stock Price Target $290.00
- High Stock Price Target $465.00
- Low Stock Price Target $151.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $8.52
- Trailing P/E Ratio 25.21
- Forward P/E Ratio 25.21
- P/E Growth 25.21
- Net Income $474.62 M
Income Statement
Quarterly
Annual
Latest News of CRL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
FDA issues CRL to Astellas' IZERVAY sNDA for geographic atrophy
The FDA issued a complete response letter for Astellas Pharma's IZERVAY sNDA due to statistical concerns about proposed labelling language, not safety or efficacy. Astellas aims to address the issues ...
By Yahoo! Finance | 1 day ago -
Decoding Charles River Laboratories International Inc (CRL): A Strategic SWOT Insight
Charles River Laboratories International Inc (NYSE:CRL) displays strong financial performance despite revenue and operating income declines. The company's balance sheet remains robust, offering opport...
By Yahoo! Finance | 2 weeks ago -
Calculating The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
The analyst price target for CRL is US$224, 5.5% below their fair value estimate....
By Yahoo! Finance | 2 months ago
